JP2021515015A5 - - Google Patents

Info

Publication number
JP2021515015A5
JP2021515015A5 JP2020546378A JP2020546378A JP2021515015A5 JP 2021515015 A5 JP2021515015 A5 JP 2021515015A5 JP 2020546378 A JP2020546378 A JP 2020546378A JP 2020546378 A JP2020546378 A JP 2020546378A JP 2021515015 A5 JP2021515015 A5 JP 2021515015A5
Authority
JP
Japan
Prior art keywords
ray powder
powder diffraction
diffraction peaks
angles
crystal form
Prior art date
Application number
JP2020546378A
Other languages
English (en)
Japanese (ja)
Other versions
JP7423539B2 (ja
JPWO2019173551A5 (https=
JP2021515015A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/021080 external-priority patent/WO2019173551A1/en
Publication of JP2021515015A publication Critical patent/JP2021515015A/ja
Publication of JP2021515015A5 publication Critical patent/JP2021515015A5/ja
Publication of JPWO2019173551A5 publication Critical patent/JPWO2019173551A5/ja
Application granted granted Critical
Publication of JP7423539B2 publication Critical patent/JP7423539B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020546378A 2018-03-07 2019-03-07 Sgc刺激因子の結晶形態 Active JP7423539B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862639846P 2018-03-07 2018-03-07
US62/639,846 2018-03-07
PCT/US2019/021080 WO2019173551A1 (en) 2018-03-07 2019-03-07 Crystalline forms of an sgc stimulator

Publications (4)

Publication Number Publication Date
JP2021515015A JP2021515015A (ja) 2021-06-17
JP2021515015A5 true JP2021515015A5 (https=) 2022-03-14
JPWO2019173551A5 JPWO2019173551A5 (https=) 2022-03-14
JP7423539B2 JP7423539B2 (ja) 2024-01-29

Family

ID=65818696

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020546378A Active JP7423539B2 (ja) 2018-03-07 2019-03-07 Sgc刺激因子の結晶形態

Country Status (21)

Country Link
US (3) US11466015B2 (https=)
EP (1) EP3762389B1 (https=)
JP (1) JP7423539B2 (https=)
KR (1) KR102782810B1 (https=)
CN (1) CN111836812A (https=)
AU (1) AU2019231724B2 (https=)
BR (1) BR112020018212A2 (https=)
CA (1) CA3092683A1 (https=)
CL (5) CL2020002284A1 (https=)
CO (1) CO2020012493A2 (https=)
CR (1) CR20200458A (https=)
EA (1) EA202092109A1 (https=)
ES (1) ES2980256T3 (https=)
IL (1) IL276853B1 (https=)
MA (1) MA54638A (https=)
MX (5) MX2023004858A (https=)
PE (1) PE20210124A1 (https=)
PH (1) PH12020551394A1 (https=)
SG (1) SG11202008641WA (https=)
TW (1) TWI823903B (https=)
WO (1) WO2019173551A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019231724B2 (en) 2018-03-07 2024-06-27 Tisento Therapeutics Inc. Crystalline forms of an sGC stimulator
KR20210031931A (ko) * 2018-07-11 2021-03-23 사이클리온 테라퓨틱스, 인크. 미토콘드리아 장애의 치료를 위한 sGC 자극제의 용도
US20230130739A1 (en) * 2020-03-26 2023-04-27 Cyclerion Therapeutics, Inc. DEUTERATED sGC STIMULATORS
EP4640676A1 (en) * 2022-12-21 2025-10-29 Sunshine Lake Pharma Co., Ltd. Crystal form of fluorine-substituted indazole compound and use thereof
AU2023412238A1 (en) * 2022-12-21 2025-07-03 Sunshine Lake Pharma Co., Ltd. Crystal form of fluorine-substituted indazole compound and use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 1−(置換ベンジル)−3−(置換アリール)縮合ピラゾール類、その製造法及びその用途
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
CN1332943C (zh) 1998-07-08 2007-08-22 萨诺费-阿文蒂斯德国有限公司 硫取代的磺酰基氨基羧酸n-芳基酰胺,其制备方法、用途以及含有该化合物的药物制剂
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
KR20100059952A (ko) 2007-09-06 2010-06-04 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 사이클라제 활성제
WO2009094242A1 (en) 2008-01-24 2009-07-30 Merck & Co., Inc. Angiotensin ii receptor antagonists
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CN102414194A (zh) 2009-02-26 2012-04-11 默沙东公司 可溶性鸟苷酸环化酶激活剂
US9284301B2 (en) 2010-03-25 2016-03-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
UA107112C2 (uk) 2010-05-27 2014-11-25 Мерк Шарп Енд Доме Корп. Активатори розчинної гуанілатциклази
AR088020A1 (es) 2010-06-30 2014-05-07 Ironwood Pharmaceuticals Inc Compuestos heterociclicos como estimuladores de sgc
EP2632551B1 (en) 2010-10-28 2016-07-06 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2637659B1 (en) 2010-11-09 2016-05-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CA2891976C (en) 2012-11-30 2020-07-21 Astellas Pharma Inc. Imidazopyridine compounds
US9776997B2 (en) 2013-06-04 2017-10-03 Bayer Pharma Aktiengesellschaft 3-aryl-substituted imidazo[1,2-A]pyridines and their use
CN104327107A (zh) 2013-10-17 2015-02-04 广东东阳光药业有限公司 一种氟喹诺酮类抗菌药物的制备方法
US9796733B2 (en) 2014-06-04 2017-10-24 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
EP3194386A2 (en) 2014-09-17 2017-07-26 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CN107257796A (zh) * 2014-12-02 2017-10-17 拜耳医药股份有限公司 取代的吡唑并[1,5‑a]吡啶和咪唑并[1,2‑a]吡嗪及其用途
CR20220309A (es) * 2016-09-02 2022-09-16 Cyclerion Therapeutics Inc Estimuladores de sgc
AU2019231724B2 (en) 2018-03-07 2024-06-27 Tisento Therapeutics Inc. Crystalline forms of an sGC stimulator

Similar Documents

Publication Publication Date Title
JP2021515015A5 (https=)
JP2013237682A5 (https=)
JP2012067131A5 (https=)
WO2018081417A3 (en) PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
HRP20120066T1 (hr) Kalijeva sol inhibitora hiv integraze
JP2006316058A5 (https=)
CA2608018A1 (en) Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
RU2009136593A (ru) Кристаллические формы 6-[2-(метилкарбамоил)фенилсульфанил]-3-е-[2-(пиридин-2-ил)этенил]индазола, пригодные для лечения аномального роста клеток у илекопитаюших
JP2018501315A5 (https=)
JP2018516883A5 (https=)
JP2018168191A5 (https=)
JP2015010091A5 (https=)
JP2020536893A5 (https=)
JP2015522037A5 (https=)
JP2023109937A5 (https=)
JP2007532560A5 (https=)
KR20170068596A (ko) 트리시클릭 회전장애이성질체 화합물
PH12020551394A1 (en) CRYSTALLINE FORMS OF AN sGC STIMULATOR
JP2011527687A5 (https=)
JP2016537326A5 (https=)
JPWO2019173551A5 (https=)
JP2018516946A5 (https=)
JP2016510767A5 (https=)
JP2019516791A5 (https=)
JP2004530660A5 (https=)